<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04224493</url>
  </required_header>
  <id_info>
    <org_study_id>EZH-302</org_study_id>
    <nct_id>NCT04224493</nct_id>
  </id_info>
  <brief_title>Study in Subjects With Relapsed/Refractory Follicular Lymphoma</brief_title>
  <official_title>A Phase 1b/3 Double-blind, Randomized, Active-controlled, 3-stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination With Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epizyme, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Epizyme, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, double-blind, active-controlled, randomized, 3-stage, biomarker&#xD;
      enrichment design featuring early futility stopping and sample-size re-estimation with safety&#xD;
      run-in designed to evaluate the efficacy and safety of tazemetostat in combination with R2 in&#xD;
      subjects with R/R FL, who have completed at least 1 prior systemic chemotherapy,&#xD;
      immunotherapy, or chemoimmunotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stage 1 is a safety run-in phase, stage 2 is an efficacy and safety phase for an assessment&#xD;
      of the EZH2 Mutant Type population and overall FL population regardless of EZH2 mutation&#xD;
      status, and optional stage 3 with efficacy and safety phase for subjects with EZH2 mutation.&#xD;
      Stage 3 with Mutant Type population alone will be executed in case the efficacy of the&#xD;
      overall population in stage 2 fails whilst the efficacy of EZH2 Mutant Type is sufficiently&#xD;
      promising. Stage 2 will include 2 futility interim analyses based on ORR for the first&#xD;
      futility and PFS for the second one. In addition, there is a possible sample size&#xD;
      re-estimation based on PFS. This is to ensure early detection of the presence/absence of&#xD;
      clinical efficacy benefit as well as ensuring adequate powering based on the trial results to&#xD;
      demonstrate a meaningful efficacy difference.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2019</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stage 1: RP3D of tazemetostat in combination with R2</measure>
    <time_frame>Each cohort minimum 3 subjects. Evaluated for DLTs during the first 28 day cycle. 2-3 subjects 1 of the 6 subjects in the cohort experiences a DLT, the next dose level/cohort will be assessed. The RP3D for Phase 3 will be selected at in cohort experience</time_frame>
    <description>The safety and tolerability of tazemetostat in combination with R2 in subjects with R/R FL will be evaluated. RP3D of tazemetostat for further evaluation in phase 3 will be selected as assessed by the occurrence of treatment-emergent dose-limiting toxicities (DLTs) and adverse events (AEs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 2: Progression-free Survival (PFS)</measure>
    <time_frame>Time from the date of randomization to the time of confirmed disease progression per the 2014 Lugano Classification (Cheson, 2014) or death, whichever occurs first, assessed up to 72 months.</time_frame>
    <description>Evaluate and compare progression-free survival (PFS), as assessed by Investigators, of tazemetostat + R2 versus placebo + R2 in subjects with R/R FL who have completed at least 1 prior systemic chemotherapy, immunotherapy, or chemoimmunotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of tazemetostat Maximum Plasma Concentration Cmax.</measure>
    <time_frame>Stage 1: Cycles 1 &amp; 2 , days 1 &amp; 15. (Each cycles is 28 days)</time_frame>
    <description>Assess the pharmacokinetics of tazemetostat when administered concomitantly with R2 in subjects with R/R FL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>R2 arm (n = 178) versus investigator assessment of 14.3 months and 14.1 months by IRC in the placebo plus rituximab arm (n = 180) with a hazard ratio (HR) of 0.51 and 0.46, respectiv</time_frame>
    <description>Stage 2: Evaluate and compare PFS by blinded independent review committee (IRC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>up to 72 months</time_frame>
    <description>Stage 2: Evaluate and compare objective response rate (ORR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2: Duration of response</measure>
    <time_frame>Through study of completion, up to 72 months</time_frame>
    <description>Evaluate and compare the duration of response (DOR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2: Duration of complete response</measure>
    <time_frame>Through study of completion, up to 72 hours</time_frame>
    <description>Evaluate and compare the duration of complete response (DOCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>Through study of completion, up to 72 hours</time_frame>
    <description>Stage 2: Evaluate and compare the disease control rate (DCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From day of randomization until death due to any cause or study completion, up to 72 months. o 72 hours</time_frame>
    <description>Stage 2: Evaluate and compare the overall survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQOL</measure>
    <time_frame>Measured at Screening, on Day 1 and Day 15 of Cycles 1 and 2, on Day 1 and optionally on Day 15 of each cycle from Cycle 3 and beyond, and at end of treatment visit, up to 3 years. (Each cycle is 28 days)</time_frame>
    <description>Stage 2: Evaluate and compare health-related quality of life as measured by the EuroQOL 5-Dimension 5-Level (EQ-5D-5L) instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>From date of consent until 30 days after discontinuation of study treatment, up to 72 months.</time_frame>
    <description>Stage 2: Evaluate and compare safety and tolerability between tazemetostat + R2 vs Placebo + R2.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">518</enrollment>
  <condition>Relapsed/Refractory Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>Tazemetostat + R2 Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tazemetostat RP3D administered PO twice daily in continuous 28-day cycles.&#xD;
rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1; then on day 1 of cycles 2 to 5.&#xD;
lenalidomide 20 mg (if creatinine clearance ≥60 mL/minute) or 10 mg (if creatinine clearance &lt;60 mL/minute), administered PO QD on days 1 to 21 for 12 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + R2 Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo administered PO twice daily in continuous 28-day cycles.&#xD;
rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1; then on day 1 of cycles 2 to 5.&#xD;
lenalidomide 20 mg (if creatinine clearance ≥60 mL/minute) or 10 mg (if creatinine clearance &lt;60 mL/minute), administered PO QD on days 1 to 21 for 12 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazemetostat</intervention_name>
    <description>Tazemetostat RP3D (tablets) administered PO twice daily in continuous 28-day cycles for 12 cycles.</description>
    <arm_group_label>Tazemetostat + R2 Arm</arm_group_label>
    <other_name>EPZ-6438</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo tablets administered PO twice daily in continuous 28-day cycles for 12 cycles.</description>
    <arm_group_label>Placebo + R2 Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Lenalidomide 20 mg capsules (if creatinine clearance ≥60 mL/minute) or 10 mg capsules (if creatinine clearance &lt;60 mL/minute), administered PO QD on days 1 to 21 for 12 cycles.</description>
    <arm_group_label>Placebo + R2 Arm</arm_group_label>
    <arm_group_label>Tazemetostat + R2 Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1; then on day 1 of cycles 2 to 5.</description>
    <arm_group_label>Placebo + R2 Arm</arm_group_label>
    <arm_group_label>Tazemetostat + R2 Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have voluntarily agreed to provide written informed consent and demonstrated&#xD;
             willingness and ability to comply with all aspects of the protocol.&#xD;
&#xD;
          2. Males or females are ≥18 years of age at the time of providing voluntary written&#xD;
             informed consent.&#xD;
&#xD;
          3. Life expectancy ≥3 months before enrollment.&#xD;
&#xD;
          4. Subjects with a history of hepatitis B or C are eligible on the condition that&#xD;
             subjects have adequate liver function as defined by Inclusion Criterion #15 and are&#xD;
             hepatitis B surface antigen negative and/or have undetectable hepatitis C virus (HCV)&#xD;
             RNA.&#xD;
&#xD;
          5. Have histologically confirmed FL, grades 1 to 3A.&#xD;
&#xD;
          6. Must have been previously treated with at least 1 prior systemic chemotherapy,&#xD;
             immunotherapy, or chemoimmunotherapy:&#xD;
&#xD;
               1. Systemic therapy includes treatments such as:&#xD;
&#xD;
             i. Rituximab monotherapy ii. Chemotherapy given with or without rituximab iii.&#xD;
             Radioimmunoconjugates such as 90Y-ibritumomab tiuxetan and 131I-tositumomab.&#xD;
&#xD;
             b. Systemic therapy does not include, for example: i. Local involved field&#xD;
             radiotherapy for limited-stage disease ii. Helicobacter pylori eradication Prior&#xD;
             investigational therapies will be allowed provided the subject has received at least&#xD;
&#xD;
        1 prior systemic therapy as discussed in Inclusion Criteria #6a. 7. Must have documented&#xD;
        relapsed, refractory, or PD after treatment with systemic therapy (refractory defined as&#xD;
        less than PR or disease progression &lt;6 months after last dose).&#xD;
&#xD;
        8. Have measurable disease as defined by the Lugano Classification (Cheson, 2014).&#xD;
&#xD;
        9.Time between prior anticancer therapy and first dose of tazemetostat as follows:&#xD;
&#xD;
          1. Cytotoxic chemotherapy - At least 21 days.&#xD;
&#xD;
          2. Noncytotoxic chemotherapy (eg, small molecule inhibitor) - At least 14 days.&#xD;
&#xD;
          3. Nitrosoureas - At least 6 weeks.&#xD;
&#xD;
          4. Monoclonal antibody(ies) - At least 28 days.&#xD;
&#xD;
          5. Radiotherapy -At least 6 weeks from prior radioisotope therapy; at least 12 weeks from&#xD;
             50% pelvic or total body irradiation. 13. Adequate renal function defined as&#xD;
             calculated creatinine clearance ≥40 mL/minute per the Cockcroft and Gault formula or&#xD;
             local institutional standard formula.&#xD;
&#xD;
             10. Adequate renal function defined as calculated creatinine clearance ≥40 mL/minute&#xD;
             per the Cockcroft and Gault formula or local institutional standard formula.&#xD;
&#xD;
             11. Adequate bone marrow function. 12. Females must not be lactating or pregnant at&#xD;
             Screening or Baseline (as documented by a negative beta-human chorionic gonadotropin&#xD;
             [β-hCG] test with a minimum sensitivity of 25 IU/L or equivalent units of β-hCG). A&#xD;
             separate baseline assessment is required if a negative screening pregnancy test was&#xD;
             obtained more than 72 hours before the first dose of study treatment. All females will&#xD;
             be considered to be of childbearing potential unless they are postmenopausal (at least&#xD;
             12 months consecutively amenorrhoeic, in the appropriate age group, and without other&#xD;
             known or suspected cause) or have been sterilized surgically (ie, bilateral tubal&#xD;
             ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1&#xD;
             month before dosing).&#xD;
&#xD;
             13. Females of childbearing potential must not have had unprotected sexual intercourse&#xD;
             within 30 days prior to study entry and must agree to use a highly effective method of&#xD;
             contraception, from the last menstrual period prior to randomization, during treatment&#xD;
             cycles, and for 30 days after the final dose of study treatment, and have a male&#xD;
             partner who uses a condom. Highly effective contraception includes:&#xD;
&#xD;
               -  Double barrier methods of contraception such as condom plus diaphragm or&#xD;
                  cervical/vault cap with spermicide.&#xD;
&#xD;
               -  Placement of an intrauterine device.&#xD;
&#xD;
               -  Established hormonal contraceptive methods: oral, injectable, or implant. Females&#xD;
                  who are using hormonal contraceptives must have been on a stable dose of the same&#xD;
                  hormonal contraceptive product for at least 4 weeks prior to dosing and must&#xD;
                  continue to use the same contraceptive during the study and for 30 days after&#xD;
                  study drug discontinuation.&#xD;
&#xD;
        NOTE: Female subjects exempt from this requirement are subjects who practice total&#xD;
        abstinence or have a male partner who is vasectomized. If currently abstinent, the subject&#xD;
        must agree to use a highly effective method of contraception as described above if they&#xD;
        become sexually active during treatment cycles, and for 30 days after study drug&#xD;
        discontinuation. 14. All study participants enrolled must be registered into the mandatory&#xD;
        Revlimid REMS™ program and be willing and able to comply with the requirements of the&#xD;
        Revlimid REMS™ program as appropriate for the country in which the drug is being used.&#xD;
&#xD;
        a. Female subjects of childbearing potential must adhere to the scheduled pregnancy testing&#xD;
        as required in the Revlimid REMS™ program. Female subjects exempt from this requirement are&#xD;
        subjects who have been in natural menopause for at least 2 years OR have had both ovaries&#xD;
        and/or uterus removed.&#xD;
&#xD;
        15. Male subjects must have had either a successful vasectomy OR they and their female&#xD;
        partner must meet the criteria above (ie, not of childbearing potential OR practicing&#xD;
        highly effective contraception and use a condom throughout the study period and for 30 days&#xD;
        after study drug discontinuation).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All Subjects&#xD;
&#xD;
          1. Prior exposure to tazemetostat or other inhibitor(s) of EZH2.&#xD;
&#xD;
          2. Prior exposure to lenalidomide for the treatment of FL.&#xD;
&#xD;
          3. Subjects who have mixed or transformed histology.&#xD;
&#xD;
          4. Has thrombocytopenia, neutropenia, or anemia of grade ≥3 (per CTCAE Version 5.0&#xD;
             criteria) or any prior history of myeloid malignancies, including myelodysplastic&#xD;
             syndrome (MDS).&#xD;
&#xD;
          5. Has a prior history of T-cell lymphoblastic lymphoma (T-LBL)/T-cell acute&#xD;
             lymphoblastic leukemia (T-ALL).&#xD;
&#xD;
          6. Subjects with uncontrolled leptomeningeal metastases or brain metastases or history of&#xD;
             previously treated brain metastases.&#xD;
&#xD;
          7. Subjects taking medications that are known potent cytochrome P450 (CYP)3A4&#xD;
             inducers/inhibitors (including St. John's wort) (Flockhart, 2007; U. S. Food and Drug&#xD;
             Administration, February 2015).&#xD;
&#xD;
          8. Are unwilling to exclude Seville oranges, grapefruit juice, AND grapefruit from their&#xD;
             diet.&#xD;
&#xD;
          9. Major surgery within 4 weeks before the first dose of study drug.&#xD;
&#xD;
             a. Note: Minor surgery (eg, minor biopsy of extracranial site, central venous catheter&#xD;
             placement, shunt revision) is permitted within 3 weeks prior to enrollment.&#xD;
&#xD;
         10. Are unable to take oral medication OR have malabsorption syndrome or any other&#xD;
             uncontrolled gastrointestinal condition (eg, nausea, diarrhea, vomiting) that might&#xD;
             impair the bioavailability of tazemetostat.&#xD;
&#xD;
         11. Significant cardiovascular impairment: history of congestive heart failure greater&#xD;
             than New York Heart Association (NYHA) Class II, uncontrolled arterial hypertension,&#xD;
             unstable angina, myocardial infarction, or stroke within 6 months of the first dose of&#xD;
             study drug; or cardiac ventricular arrhythmia.&#xD;
&#xD;
         12. Prolongation of corrected QT interval using Fridericia's formula (QTcF) to &gt;480 msec&#xD;
             at screening or history of long QT syndrome.&#xD;
&#xD;
         13. Venous thrombosis or pulmonary embolism within the last 3 months before starting&#xD;
             tazemetostat.&#xD;
&#xD;
             a. whereas subjects greater than 3 months since deep vein thrombosis/pulmonary&#xD;
             embolism are eligible but recommended to receive prophylaxis.&#xD;
&#xD;
         14. Have an active infection requiring systemic therapy.&#xD;
&#xD;
         15. Known hypersensitivity to any component of tazemetostat, lenalidomide, or rituximab.&#xD;
&#xD;
         16. Inability to be treated with a Pneumocystis prophylaxis medication.&#xD;
&#xD;
         17. Have an active infection with hepatitis B virus (as measured by positive hepatitis B&#xD;
             surface antigen), HCV (as measured by positive hepatitis C antibody), human&#xD;
             immunodeficiency virus, OR human T-cell lymphotropic virus 1.&#xD;
&#xD;
             a. Exceptions: Subjects with a history of hepatitis B or C who have normal ALT AND are&#xD;
             hepatitis B surface antigen negative and/or have undetectable HCV RNA.&#xD;
&#xD;
         18. Any other major illness that, in the Investigator's judgment, will substantially&#xD;
             increase the risk associated with the subject's participation in this study OR&#xD;
             interfere with their ability to receive study treatment or complete the study.&#xD;
&#xD;
         19. Female subjects who are pregnant or breastfeeding.&#xD;
&#xD;
         20. Subjects who have undergone a solid organ transplant.&#xD;
&#xD;
         21. Subjects with malignancies other than FL. a. Exception: Subjects with another&#xD;
             malignancy who have been disease-free for 5 years, or subjects with a history of a&#xD;
             completely resected non-melanoma skin cancer or successfully treated in situ carcinoma&#xD;
             are eligible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shefali Agarwal, MD</last_name>
    <phone>617-229-7575</phone>
    <email>clinicaltrials@epizyme.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southern Cancer Center</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Meshad, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC - HOPE</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sudhir Manda, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research Institute</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eddie Thara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers (RMCC) - Boulder</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Andorsky, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital and Regional Medical Center - St. Mary's</name>
      <address>
        <city>Grand Junction</city>
        <state>Colorado</state>
        <zip>81501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyle Work, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SCL Health Lutheran Medical Center</name>
      <address>
        <city>Greeley</city>
        <state>Colorado</state>
        <zip>80033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin George, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hartford Healthcare Cancer Institute The Hospital of Central Connecticut</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>06053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter D Byeff, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Hematology Consultants, PA</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamal Misleh, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Specialists, LLC Department of Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehdi M Moezi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>BRCR Medical Center, INC</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Tache, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunil Gandhi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shachar Peles, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Hawaii Moanalua Medical Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96819</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Carney, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonali Smith, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Specialists</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonard Klein, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Siouxland Regional Cancer Center</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald B Wender, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Cancer Center</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Hoffman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung T Lee, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tycell J Phillips, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose C Villasboas Bisneto, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Associates LLC -Central</name>
      <address>
        <city>East Brunswick</city>
        <state>New Jersey</state>
        <zip>08816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Fang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Care Associates-Freehold</name>
      <address>
        <city>Freehold</city>
        <state>New Jersey</state>
        <zip>07728</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nandini Ignatius, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical John Theurer Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lori Leslie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Care Associates LLC - Howell</name>
      <address>
        <city>Howell</city>
        <state>New Jersey</state>
        <zip>07731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Nahum, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Care Associates LLC - Little Silver</name>
      <address>
        <city>Little Silver</city>
        <state>New Jersey</state>
        <zip>07739</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Horkheimer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, P.C.</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mihir Raval, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Cente</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Connie Batlevi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John P Leonard, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of Rockland, P.C.</name>
      <address>
        <city>Nyack</city>
        <state>New York</state>
        <zip>10960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung Lee Lee, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute/Atrium Health</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Steven Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nashat Gabrail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care (OHC), Inc. - Kenwood Office</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Islas-Ohlmayer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Institute and Research Center - Oncology</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Sharman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Western Pennsylvania Hospital Hematology &amp; Cellular Therapy</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15524</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cyrus M Khan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand Marquess Anz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Medical Center - Cancer Institute</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radhakrishnan Ramchandren, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viralkumar Bhanderi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Flinn, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Amarillo</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Praveen Tumula, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Austin Midtown</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason M Melear, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Medical City Dallas Pediatric Hematology</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay Courtright, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moshe Y Levy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Loretta Nastoupil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Millennium Oncology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Yen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Tyler/Longview</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Habte A Yimer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology- Weslaco</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78596</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Farray-Berges, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Connor, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Assistant professor of medicine - Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adolfo Diaz Duque, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute; The University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harsh Shah, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Specialists of Tidewater - Chesapeake Office</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William MacLaughlin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fairfax Northern Virginia Hematology Oncology PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitul Gandhi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Associates of Southwest Virginia</name>
      <address>
        <city>Low Moor</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Gillespie-Twardy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multicare Health System</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Brett Gourley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 12, 2019</study_first_submitted>
  <study_first_submitted_qc>January 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

